1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid (pyridin-2-ylmethyl)-amide | 1194018-03-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid (pyridin-2-ylmethyl)-amide
• 英文别名: 1-(4-fluorophenyl)-N-(pyridin-2-ylmethyl)indazole-4-carboxamide
• CAS: 1194018-03-5
• 化学式: C₂₀H₁₅FN₄O
• 分子量: 346.364
• InChiKey: FNMJIMHKTYMVKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  26
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  59.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  1H-吲唑-4-羧酸 在 盐酸 、 trimethylsilyldiazomethane 、 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 三乙胺 作用下， 生成 1-(4-fluoro-phenyl)-1H-indazole-4-carboxylic acid (pyridin-2-ylmethyl)-amide
  参考文献：
  名称：

  Identification of novel azaindazole CCR1 antagonist clinical candidates

  摘要：

  Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.

  DOI：

  10.1016/j.bmcl.2018.12.024

文献信息

• Indazole Compounds As CCR1 Receptor Antagonists
  申请人：KUZMICH Daniel

  公开号：US20110294808A1

  公开（公告）日：2011-12-01

  Disclosed indazoles compounds that are useful as antagonists of CCR1 activity and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

  公开了一种吲唑化合物，可用作CCR1活性的拮抗剂，因此可用于治疗通过CCR1活性介导或维持的各种疾病和障碍，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。还公开了包含这些化合物的制药组合物，使用这些化合物治疗各种疾病和障碍的方法，制备这些化合物的过程以及在这些过程中有用的中间体。
• INDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2285783A1

  公开（公告）日：2011-02-23
• US8008327B2
  申请人：——

  公开号：US8008327B2

  公开（公告）日：2011-08-30
• US8263597B2
  申请人：——

  公开号：US8263597B2

  公开（公告）日：2012-09-11
• Identification of novel azaindazole CCR1 antagonist clinical candidates
  作者：Christian Harcken、Daniel Kuzmich、Brain Cook、Can Mao、Darren Disalvo、Hossein Razavi、Alan Swinamer、Pingrong Liu、Qiang Zhang、Alison Kukulka、Donna Skow、Mita Patel、Monica Patel、Kimberly Fletcher、Tara Sherry、David Joseph、Dustin Smith、Melissa Canfield、Donald Souza、Matthew Bogdanffy、Karen Berg、Maryanne Brown

  DOI：10.1016/j.bmcl.2018.12.024

  日期：2019.2

  Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.